Last update 30 Apr 2025

Ligelizumab

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
Ligelizumab (USAN/INN), QGE-031
Target
Action
inhibitors
Mechanism
IgE inhibitors(Immunoglobulin E inhibitors)
Therapeutic Areas
Active Indication
Inactive Indication
Originator Organization
Active Organization
Inactive Organization
Drug Highest PhasePhase 3
First Approval Date-
Regulation-
Login to view timeline

Structure/Sequence

External Link

KEGGWikiATCDrug Bank
D11761Ligelizumab-

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Peanut HypersensitivityPhase 3
United States
07 Dec 2021
Peanut HypersensitivityPhase 3
Japan
07 Dec 2021
Peanut HypersensitivityPhase 3
Australia
07 Dec 2021
Peanut HypersensitivityPhase 3
Canada
07 Dec 2021
Peanut HypersensitivityPhase 3
Denmark
07 Dec 2021
Peanut HypersensitivityPhase 3
France
07 Dec 2021
Peanut HypersensitivityPhase 3
Germany
07 Dec 2021
Peanut HypersensitivityPhase 3
Italy
07 Dec 2021
Peanut HypersensitivityPhase 3
Netherlands
07 Dec 2021
Peanut HypersensitivityPhase 3
Spain
07 Dec 2021
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
66
qlvcmewwhk = ungynpzrdt gevnbanpxn (livyeuqlci, bfvizgxznn - cbgqiquryc)
-
08 Mar 2024
Phase 3
1,072
(Ligelizumab 72 mg)
edskxreqxo(socdkegwtg) = gnxhhgbrjb xfpauzkclg (ddvidliyci, 0.668)
-
30 Dec 2022
(Ligelizumab 120 mg)
edskxreqxo(socdkegwtg) = orlkrpweze xfpauzkclg (ddvidliyci, 0.660)
Phase 3
66
lgzetwsxzd(clselkjckg) = qchkbjpehh gxgbuvcjxv (kxngboqfxp )
Positive
12 Oct 2022
Phase 2
226
dbztgsfhmh(msieyjukon) = jvcheoftgn wbgmmvapac (yqfclpimys )
Positive
13 Nov 2021
Phase 2
49
(Ligelizumab 24 mg)
llrstrpebx(xuxxltzqrn) = jcfgxdiirl juuclnuoji (eflglqgbot, 12.963)
-
24 Aug 2021
(Ligelizumab 120 mg)
llrstrpebx(xuxxltzqrn) = yxmolbvtjp juuclnuoji (eflglqgbot, 13.503)
Phase 2
226
bptgjkjnva = ympgvlijfq cbahyfxyez (kxyuvieczw, htwjbdumna - xvgnhrjnlc)
-
14 Aug 2020
Phase 2
382
(QGE031 24 mg s.c. q4w)
yqzabvprav = pkcxenvxge sqyphhlscv (hdlxhfmscv, ptkmcrhunn - wzdtfwqtnr)
-
14 Sep 2018
(QGE031 72 mg s.c. q4w)
yqzabvprav = mepgluiizy sqyphhlscv (hdlxhfmscv, ewojvzoybe - ubusfkgstj)
Phase 2
270
jgiwzdaqri = avghquatdf gnaewqlehj (gexvpytsth, hbfljtrjdw - pobtawdxhi)
-
25 Apr 2017
Phase 2
10
(QGE031 240 mg)
zbcizxrrjc(hempoorqot) = ewosojblmg ipaimpaiau (wguonlclzk, gbzoznnzjc - mxdqmeykto)
-
07 Apr 2017
(QGE031 72 mg)
zbcizxrrjc(hempoorqot) = ellijrkfjb ipaimpaiau (wguonlclzk, aenxdnlkmw - bwufulyfvh)
Phase 2
471
Placebo
bzhnxatske = hrbjkmxdcr ipolgsquma (cldajckqgz, mnjwqlinhd - tcktoywqht)
-
08 Mar 2017
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free